معرفی
Dr. Gerhard Leinenga is a Postdoctoral Research Fellow at the Queensland Brain Institute (QBI), The University of Queensland. His research focuses on developing non-invasive therapeutic strategies for neurodegenerative diseases, particularly Alzheimer's disease, using focused ultrasound technologies. His work emphasizes the role of ultrasound in enhancing drug delivery across the blood-brain barrier, modulating amyloid-beta and tau pathologies, and restoring cognitive functions in mouse models. Key contributions include demonstrating the efficacy of scanning ultrasound in clearing amyloid plaques and improving memory without requiring amyloid reduction, as well as investigating tau protein clearance mechanisms.
Dr. Leinenga earned his PhD from The University of Queensland in 2017, where his thesis explored the effects of scanning focused ultrasound in Alzheimer's mouse models. His research has been published in high-impact journals such as Science Translational Medicine, Molecular Psychiatry, and Theranostics, and he has contributed to datasets analyzing ultrasound-mediated improvements in APP23 mice.
His work bridges engineering and neuroscience, with a focus on translating ultrasound-based therapies to clinical applications. Recent studies highlight the potential of combining ultrasound with antibody therapies to target tau pathology, showcasing interdisciplinary collaboration with experts in neurology, immunology, and biomedical engineering.
